AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
|
Homo sapiens |
GSE28126
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
AR stimulated |
Permissive
Robust
|
Homo sapiens |
GSE28126
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
Vehicle |
Permissive
Robust
|
Homo sapiens |
GSE28126
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
AR stimulated |
Permissive
Robust
|
Homo sapiens |
GSE28126
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
NT |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
siERG |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
10nm R |
Permissive
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1nm R |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
ethanol |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
ethanol |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1000 nM Bica |
Permissive
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
100 nM DHT |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
100 nM DHT+Dex |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1000 nM CPA |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1000 nM RU486 |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
100 nM DHT |
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT for 4h |
Permissive
Robust
|
Homo sapiens |
GSE32345
...
|
MA0007.3
|
AR |
VCS2 (prostate carcinoma) |
DHT for 4h |
Permissive
Robust
|
Homo sapiens |
GSE32345
...
|
MA0007.3
|
AR |
kidney |
castrated+vehicle |
Permissive
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
caput epididymis |
castrated+vehicle |
Permissive
Robust
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
prostate |
castrated+vehicle |
Permissive
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
prostate |
castrated+testosterone |
Permissive
Robust
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
kidney |
castrated+testosterone |
Permissive
Robust
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
caput epididymis |
intact |
Permissive
Robust
|
Mus musculus |
GSE47192
...
|
MA0007.3
|
AR |
caput epididymis |
specificity affecting androgen receptor knock-in |
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
caput epididymis |
specificity affecting androgen receptor knock-in |
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
ventral prostate |
specificity affecting androgen receptor knock-in |
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
BICALUTAMIDE |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
BICALUTAMIDE |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
BICALUTAMIDE |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
BICALUTAMIDE |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Vehicle |
Permissive
Robust
|
Homo sapiens |
GSE49832
...
|
MA0007.3
|
AR |
HEK293 (embryonic kidney) |
Ethanol |
Permissive
|
Homo sapiens |
GSE54109
...
|
MA0007.3
|
AR |
HEK293 (embryonic kidney) |
10 nM R1881 |
Permissive
Robust
|
Homo sapiens |
GSE54109
...
|
MA0007.3
|
AR |
HEK293 (embryonic kidney) |
10 nM R1881 |
Permissive
Robust
|
Homo sapiens |
GSE54109
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Bicalutamide |
Permissive
Robust
|
Homo sapiens |
GSE51063
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Enzalutamide |
Permissive
|
Homo sapiens |
GSE51063
...
|
MA0007.3
|
AR |
LNCaP C4-2 (prostate carcinoma) |
ethanol |
Permissive
|
Homo sapiens |
GSE55031
...
|
MA0007.3
|
AR |
LNCaP C4-2 (prostate carcinoma) |
10 nmol/l of mibolerone |
Permissive
Robust
|
Homo sapiens |
GSE55031
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
ethanol |
Permissive
Robust
|
Homo sapiens |
GSE55031
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
10 nmol/l of mibolerone |
Permissive
Robust
|
Homo sapiens |
GSE55031
...
|
MA0007.3
|
AR |
ovarian granulosa cells |
Insertion |
Permissive
|
Homo sapiens |
GSE58628
...
|
MA0007.3
|
AR |
ovarian granulosa cells |
Deletion |
Permissive
|
Homo sapiens |
GSE58628
...
|
MA0007.3
|
AR |
CWR22 (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE62442
...
|
MA0007.3
|
AR |
CWR22 (prostate carcinoma) |
DHT+Bicalutamide |
Permissive
Robust
|
Homo sapiens |
GSE62442
...
|
MA0007.3
|
AR |
CWR22 (prostate carcinoma) |
DHT+MDV3100 |
Permissive
Robust
|
Homo sapiens |
GSE62442
...
|
MA0007.3
|
AR |
prostate tumor |
castrate |
Permissive
|
Mus musculus |
GSE62645
...
|
MA0007.3
|
AR |
prostate tumor |
bicalutamide |
Permissive
Robust
|
Mus musculus |
GSE62645
...
|
MA0007.3
|
AR |
prostate tumor |
enzalutamide |
Permissive
|
Mus musculus |
GSE62645
...
|
MA0007.3
|
AR |
LNCaP C4-2 (prostate carcinoma) |
ethanol |
Permissive
|
Homo sapiens |
GSE65066
...
|
MA0007.3
|
AR |
LNCaP C4-2 (prostate carcinoma) |
10 nmol/l of mibolerone |
Permissive
Robust
|
Homo sapiens |
GSE65066
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
ethanol |
Permissive
Robust
|
Homo sapiens |
GSE65066
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
10 nmol/l of mibolerone |
Permissive
Robust
|
Homo sapiens |
GSE65066
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Bicalutamide 1 μM |
Permissive
|
Homo sapiens |
GSE66037
...
|
MA0007.3
|
AR |
BicR (prostate cancer) |
DHT 10 nM |
Permissive
Robust
|
Homo sapiens |
GSE66037
...
|
MA0007.3
|
AR |
BicR (prostate cancer) |
Bicalutamide 1 μM |
Permissive
|
Homo sapiens |
GSE66037
...
|
MA0007.3
|
AR |
BicR (prostate cancer) |
ethanol |
Permissive
|
Homo sapiens |
GSE66037
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
siControl |
Permissive
Robust
|
Homo sapiens |
GSE77770
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
siOCT1 |
Permissive
Robust
|
Homo sapiens |
GSE77770
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
siControl |
Permissive
Robust
|
Homo sapiens |
GSE77770
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
siOCT1 |
Permissive
Robust
|
Homo sapiens |
GSE77770
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
72 hour CDT + 3 hour EtOH |
Permissive
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
treated for 24 hours with 0.5μM PD-0332991 +3 hour 10nm DHT |
Permissive
Robust
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
treated for 24 hours with 5μg/mL roscovitine + 3 hour DHT |
Permissive
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
treated for 24 hours with 2μg/mL aphidicolin +3 hour 10nm DHT |
Permissive
Robust
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
treated for 24 hours with 1mM hydroxyurea +3 hour 10nm DHT |
Permissive
Robust
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
2μg/mL aphidicolin for 15 hours, followed by washout and treatment with 50ng/mL nocodozole for 9 hours +3 hour 10nm DHT |
Permissive
Robust
|
Homo sapiens |
GSE82202
...
|
MA0007.3
|
AR |
R1-D567 (prostate cancer) |
radiation |
Permissive
Robust
|
Homo sapiens |
GSE102164
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE73994
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881+Doxycycline |
Permissive
Robust
|
Homo sapiens |
GSE73994
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
NOV induced |
Permissive
Robust
|
Homo sapiens |
GSE79357
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
dihydrotestosterone (DHT) |
Permissive
Robust
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
Control |
Permissive
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
dihydrotestosterone (DHT) |
Permissive
Robust
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Control |
Permissive
Robust
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
dihydrotestosterone (DHT) |
Permissive
Robust
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Control |
Permissive
|
Homo sapiens |
GSE92347
...
|
MA0007.3
|
AR |
breast tumor |
Female |
Permissive
Robust
|
Homo sapiens |
GSE104399
...
|
MA0007.3
|
AR |
MCF-7 C4-12 (invasive breast ductal carcinoma) |
Female |
Permissive
Robust
|
Homo sapiens |
GSE104399
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation , ethanol, knockout control Genotype: wildtype Source: prostate cancer cells |
Permissive
Robust
|
Homo sapiens |
GSE108144
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol, shTRIM24 Genotype: wildtype Source: prostate cancer cells |
Permissive
Robust
|
Homo sapiens |
GSE108144
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol , shTRIM28 Genotype: wildtype Source: prostate cancer cells |
Permissive
|
Homo sapiens |
GSE108144
...
|
MA0007.3
|
AR |
HEE (human epididymis epithelial cells) |
Treatment: without treatment of R1881 (methyltrienolone) |
Permissive
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
AR |
HEE (human epididymis epithelial cells) |
Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
AR |
HEE (human epididymis epithelial cells) |
Treatment: without treatment of R1881 (methyltrienolone) |
Permissive
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
AR |
HEE (human epididymis epithelial cells) |
Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
AR |
A375 (malignant melanoma) |
Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) empty vector control for 24 hr, post-seeding using Lipofectamine 2000 |
Permissive
|
Homo sapiens |
GSE116189
...
|
MA0007.3
|
AR |
A375 (malignant melanoma) |
Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) vector expressing SLNCR1 for 24 hr, post-seeding using Lipofectamine 2000 |
Permissive
|
Homo sapiens |
GSE116189
...
|
MA0007.3
|
AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: EPZ-6438 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: non-target siNT+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
treatment: targeting ARV1/3/4/7 siARVs+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: targeting AR exon 7 siARFL+ ethanol |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: wildtype |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: wildtype |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G |
Permissive
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
AR |
hNSC (neural stem cells) |
Treatment: DMSO 4 hours |
Permissive
|
Homo sapiens |
GSE86454
...
|
MA0007.3
|
AR |
hNSC (neural stem cells) |
Treatment: DHT 10nM 4 hours |
Permissive
|
Homo sapiens |
GSE86454
...
|
MA0007.3
|
AR |
hNSC (neural stem cells) |
Treatment: Testosterone 100nM 4 hours |
Permissive
|
Homo sapiens |
GSE86454
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: DMSO 4 hours |
Permissive
|
Homo sapiens |
GSE86456
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: DMSO 4 hours |
Permissive
|
Homo sapiens |
GSE86456
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: DHT 100nM 4 hours |
Permissive
|
Homo sapiens |
GSE86456
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: DHT 100nM 4 hours |
Permissive
Robust
|
Homo sapiens |
GSE86456
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: control |
Permissive
Robust
|
Homo sapiens |
GSE120738
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: exclude |
Permissive
Robust
|
Homo sapiens |
GSE120738
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: case |
Permissive
Robust
|
Homo sapiens |
GSE120738
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout |
Permissive
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and vector |
Permissive
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and vector |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs Genotype: Bag-1L wildtype |
Permissive
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L wildtype |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: Ethanol for 4 hrs |
Permissive
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout |
Permissive
Robust
|
Homo sapiens |
GSE89938
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: vehicle (charcoal stripped) for 6 hrs TF: full-length AR (AR-FL) |
Permissive
Robust
|
Homo sapiens |
GSE94013
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: 10 nM DHT for 6 hrs TF: full-length AR (AR-FL) |
Permissive
Robust
|
Homo sapiens |
GSE94013
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: 10 nM DHT+ 500 nM JQ1 for 6 hrs TF: full-length AR (AR-FL) |
Permissive
Robust
|
Homo sapiens |
GSE94013
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
Treatment: 10 nM DHT+10 uM MDV3100 TF: full-length AR (AR-FL) |
Permissive
Robust
|
Homo sapiens |
GSE94013
...
|
MA0007.3
|
AR |
HIV-1 latently-infected central memory T cells cultured from uninfected primary T cells |
Treatment: 24h ethanol |
Permissive
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 24h DHT 1 nM |
Permissive
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
LTAD (long term androgen deprivation) |
Treatment: 24h DHT 1 nM |
Permissive
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
VCaP and LTAD cells |
Treatment: 24h DHT 10 nM |
Permissive
Robust
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
VCaP and LTAD cells |
Treatment: 24h DHT 1 nM |
Permissive
Robust
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
LTAD (long term androgen deprivation) |
Treatment: 24h DHT 10 nM siControl treated |
Permissive
Robust
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
LTAD (long term androgen deprivation) |
Treatment: 24h DHT 10 nM siCOBLL1 treated |
Permissive
|
Homo sapiens |
GSE94577
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: treated with 10nM vehicle for 4 hours |
Permissive
|
Homo sapiens |
GSE94682
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: treated with 10nM R1881 for 4 hours |
Permissive
Robust
|
Homo sapiens |
GSE94682
...
|
MA0007.3
|
AR |
R1-AD1 (prostate cancer) |
Treatment: 0.1% DMSO + 1 nM ethanol for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE96084
...
|
MA0007.3
|
AR |
R1-AD1 (prostate cancer) |
Treatment: 0.1% DMSO + 1 nM DHT for 4 hrs |
Permissive
|
Homo sapiens |
GSE96084
...
|
MA0007.3
|
AR |
R1-AD1 (prostate cancer) |
Treatment: 50 uM VPC14449 + 1 nM ethanol for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE96084
...
|
MA0007.3
|
AR |
R1-D567 (prostate cancer) |
Treatment: 0.1% DMSO for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE96084
...
|
MA0007.3
|
AR |
R1-D567 (prostate cancer) |
Treatment: 50 uM VPC14449 for 4 hrs |
Permissive
Robust
|
Homo sapiens |
GSE96084
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection |
Permissive
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10nM DHT for 4 hrs Genotype: shGFP |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection) |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection) |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP95 |
Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection |
Permissive
Robust
|
Homo sapiens |
GSE106559
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: transfected twice with with 5nM of siControl every 24 hours, 100nM of DHT for 2 hrs |
Permissive
Robust
|
Homo sapiens |
GSE108704
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: transfected twice with with 5nM of siControl every 24 hours, 100nM of ETOH for 2 hrs, 100nM of ETOH for 2 hrs |
Permissive
Robust
|
Homo sapiens |
GSE108704
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of DHT for 2 hrs Genotype: transfected with siLINC00844 |
Permissive
Robust
|
Homo sapiens |
GSE108704
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of ETOH for 2 hrs Genotype: transfected with siLINC00844 |
Permissive
|
Homo sapiens |
GSE108704
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: FA (control) |
Permissive
Robust
|
Homo sapiens |
GSE114737
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 2 mM DSG for 25 mins |
Permissive
Robust
|
Homo sapiens |
GSE114737
...
|
MA0007.3
|
AR |
primary prostate cancer |
Treatment: FA (control) |
Permissive
Robust
|
Homo sapiens |
GSE114737
...
|
MA0007.3
|
AR |
primary prostate cancer |
Treatment: 2 mM DSG for 25 mins |
Permissive
Robust
|
Homo sapiens |
GSE114737
...
|
MA0007.3
|
AR |
primary prostate cancer |
Treatment: 2 mM DSG for 25 mins |
Permissive
Robust
|
Homo sapiens |
GSE114737
...
|
MA0007.3
|
AR |
caput epididymis |
Age: 3 months Strain: C57Bl/6N; 129 hybrid Genotype: wildtype Tissue: Caput epididymis (containing initial segment) |
Permissive
Robust
|
Mus musculus |
GSE121151
...
|
MA0007.3
|
AR |
caput epididymis |
Age: 3 months Strain: C57Bl/6N; 129 hybrid Genotype: ArKI Tissue: Caput epididymis (containing initial segment) |
Permissive
Robust
|
Mus musculus |
GSE121151
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: vehicle, control; |
Permissive
|
Homo sapiens |
GSE43720
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Treatment: 10 nm DHT; |
Permissive
Robust
|
Homo sapiens |
GSE43720
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Genotype: Renilla knockout; Treatment: shRenilla; |
Permissive
Robust
|
Homo sapiens |
GSE120680
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
Genotype: GREB1 knockout; Treatment: shGREB1; |
Permissive
Robust
|
Homo sapiens |
GSE120680
...
|
MA0007.3
|
AR |
prostate cancer |
Strain:: 129/C57Bl6; Treatment: CRISPR-AR; Genotype: Pten-/- Rosa26-Tmprss2-ERG, AR knockout; |
Permissive
|
Mus musculus |
GSE112414
...
|
MA0007.3
|
AR |
prostate cancer |
Strain:129/C57Bl6; Treatment: CRISPR-ERG; Genotype: Pten-/- Rosa26-Tmprss2-ERG, ERG knockout; |
Permissive
Robust
|
Mus musculus |
GSE112414
...
|
MA0007.3
|
AR |
sperm |
Strain: CD1; |
Permissive
|
Mus musculus |
GSE116855
...
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
SHFOXA1 |
Permissive
|
Homo sapiens |
ERP003272
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
KDP53 |
Permissive
Robust
|
Homo sapiens |
GSE31294
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE47120
|
MA0007.3
|
AR |
|
FOXA1_HOXB13 |
Permissive
Robust
|
Homo sapiens |
GSE56288
|
MA0007.3
|
AR |
prostate |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE61838
|
MA0007.3
|
AR |
DUCaP (prostate carcinoma) |
ANDROGEN |
Permissive
Robust
|
Homo sapiens |
GSE70679
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
metastatic prostate cancer tissue |
|
Permissive
Robust
|
Homo sapiens |
GSE14092
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE39879
...
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Mus musculus |
GSE47119
...
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Mus musculus |
GSE47119
...
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Mus musculus |
GSE47119
...
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Mus musculus |
GSE47119
...
|
MA0007.3
|
AR |
caput epididymis |
|
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
caput epididymis |
|
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
ventral prostate |
|
Permissive
Robust
|
Mus musculus |
GSE51106
...
|
MA0007.3
|
AR |
non-proliferating proximal caput epididymus |
|
Permissive
|
Mus musculus |
GSE38656
...
|
MA0007.3
|
AR |
ovarian granulosa cells |
|
Permissive
Robust
|
Homo sapiens |
GSE58628
...
|
MA0007.3
|
AR |
CWR22 (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE62442
...
|
MA0007.3
|
AR |
prostate tumor |
|
Permissive
Robust
|
Mus musculus |
GSE62645
...
|
MA0007.3
|
AR |
R1-D567 (prostate cancer) |
|
Permissive
Robust
|
Homo sapiens |
GSE102164
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE79357
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE80256
...
|
MA0007.3
|
AR |
fetal prostate fibroblasts |
|
Permissive
|
Homo sapiens |
GSE90772
...
|
MA0007.3
|
AR |
prostate cancer-associated fibroblasts |
|
Permissive
|
Homo sapiens |
GSE90772
...
|
MA0007.3
|
AR |
myofibroblasts |
|
Permissive
|
Homo sapiens |
GSE90772
...
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE96652
...
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE98809
...
|
MA0007.3
|
AR |
HDF(human dermal fibroblasts) |
|
Permissive
|
Homo sapiens |
GSE107320
...
|
MA0007.3
|
AR |
LNCaP C4-2 (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE97831
...
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ERP001226
|
MA0007.3
|
AR |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
|
Homo sapiens |
ERP001226
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ERP001226
|
MA0007.3
|
AR |
LNCaP-abl (Prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE39459
|
MA0007.3
|
AR |
|
|
Permissive
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE43785
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE45201
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE48308
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE48308
|
MA0007.3
|
AR |
|
|
Permissive
|
Homo sapiens |
GSE48308
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE48308
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE48308
|
MA0007.3
|
AR |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
|
Homo sapiens |
GSE48930
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE55062
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE55062
|
MA0007.3
|
AR |
|
|
Permissive
|
Homo sapiens |
GSE58478
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE58478
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE58478
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE63202
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE64656
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE71704
|
MA0007.3
|
AR |
|
|
Permissive
Robust
|
Homo sapiens |
GSE71704
|
MA0007.3
|
AR |
LNCaP C4-2B (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE72714
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
FOXA1 |
Permissive
Robust
|
Homo sapiens |
ERP003503
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
FOXA1 |
Permissive
|
Homo sapiens |
ERP003503
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHAT_18H |
Permissive
Robust
|
Homo sapiens |
GSE28950
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHAT_2H |
Permissive
Robust
|
Homo sapiens |
GSE28950
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1F5 |
Permissive
Robust
|
Homo sapiens |
GSE30623
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
1F5_SIFOXA1 |
Permissive
Robust
|
Homo sapiens |
GSE30623
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_10C26 |
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_10C30 |
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_1C26 |
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_1C30 |
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHCTR_R1881_HD |
Permissive
Robust
|
Homo sapiens |
GSE37345
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHFOXA1_R1881_HD |
Permissive
Robust
|
Homo sapiens |
GSE37345
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
LNCaP C4-2B (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE43720
|
MA0007.3
|
AR |
DU145 (prostate carcinoma) |
ARG56W |
Permissive
Robust
|
Homo sapiens |
GSE47987
|
MA0007.3
|
AR |
DU145 (prostate carcinoma) |
ARQ6540X |
Permissive
Robust
|
Homo sapiens |
GSE47987
|
MA0007.3
|
AR |
DU145 (prostate carcinoma) |
FOXA1_ARQ6540X |
Permissive
Robust
|
Homo sapiens |
GSE47987
|
MA0007.3
|
AR |
DU145 (prostate carcinoma) |
FOXA1_HIGH |
Permissive
Robust
|
Homo sapiens |
GSE47987
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE52725
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHGATA2 |
Permissive
Robust
|
Homo sapiens |
GSE52725
|
MA0007.3
|
AR |
PC3(bone mets prostate adenocarcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE54110
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SHPIAS1_R1881 |
Permissive
Robust
|
Homo sapiens |
GSE56086
|
MA0007.3
|
AR |
LHSAR (prostate epithelial cells) |
HOXB13 |
Permissive
Robust
|
Homo sapiens |
GSE56288
|
MA0007.3
|
AR |
LHSAR (prostate epithelial cells) |
LACZ |
Permissive
Robust
|
Homo sapiens |
GSE56288
|
MA0007.3
|
AR |
prostate |
cancer |
Permissive
Robust
|
Homo sapiens |
GSE56288
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DHT24H |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DHT24H_SHFOXA1 |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT24H |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT24H_SHFOXA1 |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT24H_SHFOXP1 |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT24H_SHRUNX1 |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
ETOH24H |
Permissive
Robust
|
Homo sapiens |
GSE58428
|
MA0007.3
|
AR |
LNCaP C4-2B (prostate carcinoma) |
ETOH_SHCTR |
Permissive
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP C4-2B (prostate carcinoma) |
R1881_SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
ETOH_SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
HOTAIR |
Permissive
Robust
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881_HOTAIR |
Permissive
Robust
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881_SHCTR |
Permissive
Robust
|
Homo sapiens |
GSE61268
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE62492
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHCTR_DHT |
Permissive
Robust
|
Homo sapiens |
GSE62492
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHFOXP1_DHT |
Permissive
Robust
|
Homo sapiens |
GSE62492
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
ETOH |
Permissive
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
R1881 |
Permissive
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
RPMIFBS |
Permissive
Robust
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHFOXA1_PHFRPMIFCS |
Permissive
Robust
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHFOXA1_RPMIFBS |
Permissive
Robust
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHGATA2_ETOH |
Permissive
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
SHGATA2_R1881 |
Permissive
|
Homo sapiens |
GSE69043
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE70161
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
R1881_SICTR |
Permissive
Robust
|
Homo sapiens |
GSE70161
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
R1881_SIPIAS1 |
Permissive
Robust
|
Homo sapiens |
GSE70161
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE74069
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
MPA |
Permissive
Robust
|
Homo sapiens |
GSE74069
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881 |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SH1_DHT |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SH1_R1881 |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SH2_DHT |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SH2_R1881 |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
SH3_DHT |
Permissive
Robust
|
Homo sapiens |
GSE79128
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DHT |
Permissive
Robust
|
Homo sapiens |
GSE83860
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DHT_TNFA |
Permissive
Robust
|
Homo sapiens |
GSE83860
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
DMSO |
Permissive
Robust
|
Homo sapiens |
GSE83860
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_30M |
Permissive
Robust
|
Homo sapiens |
GSE84432
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
R1881_4H |
Permissive
Robust
|
Homo sapiens |
GSE84432
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ERP003503
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
ERP003503
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE28950
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE32892
|
MA0007.3
|
AR |
22RV1 (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
LNCaP C4-2B (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE40050
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
|
Homo sapiens |
GSE43720
|
MA0007.3
|
AR |
DU145 (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE47987
|
MA0007.3
|
AR |
PC3(bone mets prostate adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE54110
|
MA0007.3
|
AR |
VCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE56086
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Homo sapiens |
GSE56288
|
MA0007.3
|
AR |
LNCaP (prostate carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE62492
|
MA0007.3
|
AR |
MDA-MB-453 (breast adenocarcinoma) |
|
Permissive
|
Homo sapiens |
GSE74069
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Homo sapiens |
GSE65478
|
MA0007.3
|
AR |
prostate |
|
Permissive
Robust
|
Homo sapiens |
GSE65478
|
MA0007.3
|